SMO and medulloblastoma: Ligand-independent constitutive activation of GLIs (as a consequence of loss-of-function mutations of PTCH1 or gain-of-function mutations of SMO) drives basal cell carcinoma (BCC) and Shh-type medulloblastoma development [48,49,50].